|Bid||1.1200 x 27000|
|Ask||1.1300 x 27000|
|Day's range||1.0520 - 1.1100|
|52-week range||1.0400 - 4.3500|
|Beta (5Y monthly)||2.32|
|PE ratio (TTM)||N/A|
|Earnings date||03 May 2023 - 08 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.10|
Bionano Genomics (NASDAQ: BNGO) appears to be in just that place -- at the start of its growth journey -- and it could be a great way to give your portfolio some additional upside potential. Bionano's claim to fame is its laboratory analyzer device for optical genome mapping, which it calls the Saphyr.
Image source: The Motley Fool. Bionano Genomics (NASDAQ: BNGO)Q4 2022 Earnings CallMar 09, 2023, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day and welcome to the Bionano fourth-quarter and full-year 2022 earnings conference call.
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -44.44% and 0.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?